Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________ Commission File Number 001-37687 EDITAS MEDICINE, INC. (Exact name of registrant as specified in its charter) Delawa ...

Editas Medicine, Inc. (NASDAQ:EDIT) EDIT-301 Clinical Update Conference Call June 12, 2023 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications & Investor Relations Gilmore O’Neill - Chief Executive Officer Baisong Mei - Chief Medical Officer Erick Lucera - Chief Financial Officer Conference Call Participants Joon Lee - Truist Securities Phil Nadeau - Cowen & Company Jacques Villefranc - Stifel Lisa Walter - RBC Capital Markets Jay Olson - Oppenheimer Yanan Zhu - Wells Fargo Madhu Kumar ...

Editas Medicine, Inc. (NASDAQ:EDIT) RBC Capital Markets Global Healthcare Conference 2023 May 16, 2023 10:30 AM ET Company Participants Gilmore O'Neill – Chief Executive Officer Baisong Mei – Senior Vice President and Chief Medical Officer Conference Call Participants Luca Issi – RBC Capital Markets Luca Issi All right, great, thanks. Hello, everybody. Luca Issi, Senior Biotech Analyst here at RBC Capital Markets and today is our great privilege to have Editas with us for a fireside chat. Representing the c ...

Editas Medicine, Inc. (NASDAQ:EDIT) Bank of America Global Healthcare Conference Call May 9, 2023 8:00 PM ET Company Participants Gilmore O’Neill - President, CEO & Director Conference Call Participants Gregory Harrison - Bank of America Merrill Lynch Gregory Harrison Final session of the first day of the Bank of America Healthcare Conference. I'm Greg Harrison, one of the biotech analysts here at BofA. And this afternoon, we have Editas Medicine with us represented by Gilmore O'Neill, Chief Executive Offic ...

Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2023 Results Conference Call May 5, 2023 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications and IR Gilmore O’Neill - CEO Baisong Mei - Chief Medical Officer Michelle Robertson - CFO Conference Call Participants Joon Lee - Truist Securities Samantha Semenkow - Citi Dae Gon Ha - Stifel Steve Seedhouse - Raymond James Yanan Zhu - Wells Fargo Ernie Rodriguez - Cowen Rick Bienkowski - Cantor Fitzgerald Rich Law - Credit Suisse Ry Forseth - Guggenheim ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________ Commission File Number 001-37687 EDITAS MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaw ...

Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2022 Results Conference Call February 22, 2023 8:00 AM ET Company Participants Ron Moldaver - Investor Relations Gilmore O’Neill - Chief Executive Officer Michelle Robertson - Chief Financial Officer Baisong Mei - Chief Medical Officer Conference Call Participants Samantha Semenkow - Citi Dae Gon Ha - Stifel Phil Nadeau - Cowen & Company Rick Bienkowski - Cantor Fitzgerald Jay Olson - Oppenheimer Brian Cheng - JP Morgan Luca Issi - RBC Capital Markets Greg Harrison - B ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________ Commission File Number 001-37687 EDITAS MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware ( ...

Industry/Company Involved * **Company**: Editas Medicine, Inc. (NASDAQ:EDIT) * **Industry**: Biotechnology, Gene Editing, Hematology Key Points and Arguments 1. **EDIT-301 Clinical Update**: Editas Medicine presented early clinical data from the RUBY study evaluating EDIT-301 for severe sickle cell disease (SCD) [6][7]. 2. **Safety Profile**: The initial safety profile of EDIT-301 was consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell transplant. Both dose participants showed successful engraftment and stopped red blood cell transfusions without any vaso-occlusive events (VOEs) [6]. 3. **Efficacy**: The first patient achieved a fetal hemoglobin (HBF) level of 45.4% and a total hemoglobin of 16.4 g/dL five months after EDIT-301 treatment. This suggests clinical proof of concept and potential for robust clinical benefit in SCD patients [7][8]. 4. **Mechanism of Action**: EDIT-301 uses a novel CRISPR nuclease, AsCas12a, to target the promoter region of the gamma globin gene 1 and 2, increasing fetal hemoglobin expression and mimicking the natural mechanism of hereditary persistence of fetal hemoglobin [12]. 5. **RUBY Study**: The RUBY study is a Phase 1/2 study designed to evaluate the safety, tolerability, and efficacy of EDIT-301 in severe SCD patients. The study will recruit up to 40 patients aged 18-50 years with a history of at least two VOEs per year [13]. 6. **Future Plans**: Editas Medicine plans to provide more data from the RUBY study, including data from additional patients, in the middle of 2023 [19]. Other Important Points * **Regulatory Pathway**: Editas Medicine is actively engaging with regulators and expects to have greater clarity on the required patient data set and follow-up for a BLA submission in the coming year [36]. * **Alternative Conditioning Therapies**: Editas Medicine is exploring alternative conditioning regimens beyond busulfan to reduce treatment burden for patients and treatment sites [38]. * **Clinical Differentiation**: Editas Medicine believes that its unique therapeutic strategy, including the use of AsCas12a and targeting the gamma globin promoter, could lead to significant differentiation from other SCD therapies [31]. * **Patient Engagement**: Editas Medicine values engagement with investigators, clinicians, and patient communities and believes that patient education and understanding of the science behind EDIT-301 are crucial [82].

Editas Medicine, Inc. (NASDAQ:EDIT) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Ron Moldaver - Investor Relations Gilmore O’Neill - Chief Executive Officer Baisong Mei - Chief Medical Officer Mark Shearman - Chief Scientific Officer Michelle Robertson - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Greg Harrison - Bank of America Joon Lee - Truist Securities Dae Gon Ha - Stifel Phil Nadeau - Cowen & Co. Jay Olson - Oppenheimer Joel Beatty - ...